Related Experiment Video

Updated: Dec 31, 2025

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.3K

Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?

Federica Tomao1, Giusi Santangelo1, Lucia Musacchio1

  • 1Department of Maternal and Child Health and Urological Sciences, University "Sapienza", Policlinico "Umberto I", Rome, Italy.

Journal of Cellular Physiology
|January 9, 2020
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors show promise for treating recurrent cervical cancer (CC). This review examines completed and ongoing clinical trials of PARP inhibitors in CC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Metastatic and recurrent cervical cancer (CC) present poor prognoses with limited palliative options.
  • Targeting cellular aberrations via biological pathways is key to personalized cancer therapy.
  • Poly (ADP-ribose) polymerase (PARP) enzymes are crucial for DNA repair.

Purpose of the Study:

  • To review the role of PARP inhibitors (PARPi) in cervical cancer (CC) treatment.
  • To summarize completed clinical trials and overview ongoing investigations of PARPi in CC.
  • To present established conclusions and identify future research directions for PARPi in CC.

Main Methods:

  • Literature review of clinical trials involving PARP inhibitors in cervical cancer.
  • Analysis of data from completed and ongoing studies.
  • Synthesis of findings to identify trends and future research needs.

Main Results:

  • PARP inhibitors are being investigated for gynecologic malignancies, including CC.
  • Data on PARPi efficacy in CC is evolving, with initial studies focusing on ovarian cancer.
  • Several clinical trials have been completed, with more currently underway.

Conclusions:

  • PARP inhibitors represent a developing therapeutic strategy for cervical cancer.
  • Further research is needed to fully elucidate the role and optimize the use of PARPi in CC.
  • Future studies should address specific challenges and unanswered questions in PARPi treatment for CC.
Keywords:
Parp inhibitorscervical cancergynecological cancerintraepithelial cervical lesionniraparibolaparibrucaparibveliparib

More Related Videos

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC Crosslinking of Small Molecules to Isolate Chromatin10:05

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC Crosslinking of Small Molecules to Isolate Chromatin

Published on: January 20, 2016

8.6K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.0K

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.9K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.0K